Evidence map›Paper›PMID 34919966›Full record

SynthesisIndian heart journal

Tolvaptan add-on therapy and its effects on efficacy parameters and outcomes in patients hospitalized with heart failure.

Tikal Kansara, Haresh Gandhi, Monil Majmundar, Ashish Kumar, Jignesh A Patel, Aravind Kokkirala, Norbert Moskovits, Savi Mushiyev, Craig Basman

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 8 institutions in 2 countries.

Tikal KansaraDepartment of Internal Medicine, Cleveland Clinic - Union Hospital, Dover, OH, USA. Electronic address: tikal_kansara@yahoo.co.in.
Haresh GandhiDepartment of Internal Medicine, Manmouth Medical Center, Long Branch, NJ, USA.
Monil MajmundarDepartment of Cardiology, Maimonides Hospital, New York, NY, USA.
Ashish KumarDepartment of Internal Medicine, Akron General Hospital, Akron, OH, USA.
Jignesh A PatelDepartment of Cardiology, St. Joseph's Medical Center, Stockton, CA, USA.
Aravind KokkiralaDepartment of Cardiology, Brown University - VA Medical Center, RI, USA.
Norbert MoskovitsDepartment of Cardiology, Maimonides Hospital, New York, NY, USA.
Savi MushiyevDivision of Cardiology, New York Medical College - Metropolitan Hospital Center, New York, NY, USA.
Craig BasmanDepartment of Cardiology, Lenox Hill Hospital, New York, NY, USA.
Maimonides Medical Center · USBrown University · USCleveland Clinic · USCleveland Clinic Akron General · USLenox Hill Hospital · USMonmouth Medical Center · USNew York Medical College · USSt. Joseph Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEven with the adequate use of diuretics and vasodilators, volume overload and congestion are the major causes of morbidity and mortality in patients hospitalized with acute heart failure (HF). We aim to evaluate the additive effect of tolvaptan on efficacy parameters as well as outcomes in hospitalized patients with HF.

methodsWe searched PubMed, EMBASE, Cochrane library, and Web of Science databases for randomized controlled trials that studied the effects of tolvaptan versus placebo in hospitalized patients with HF. Studies were included if they had any of the following endpoints: mortality, re-hospitalization, and in-hospital parameters like dyspnea relief, change in weight, sodium, and creatinine.

resultsThe meta-analysis analyzed data from 14 studies involving 5945 patients. The follow up duration ranged from 30 days to 2 years. Between tolvaptan and placebo groups, there was no difference in mortality and rehospitalization. HF patients had a better dyspnea relief score (Likert score) in tolvaptan group and mean reduction in weight in the first 48 h (short-term). However, at 7 days (medium-term) the mean difference in weight was not significant. Serum sodium increased significantly in tolvaptan group. There was no difference in creatinine among the two groups.

conclusionsOur meta-analysis shows that tolvaptan helps in short-term symptomatic dyspnea relief and weight reduction, but there are no long term benefits including reduction in mortality and rehospitalization.

Indexed as

Antidiuretic Hormone Receptor AntagonistsHeart FailureTolvaptanBenzazepinesHospitalizationHumansRandomized Controlled Trials as TopicAntidiuretic Hormone Receptor AntagonistsBenzazepinesTolvaptanDiureticsHeart failureTolvaptan

Identifiers

PMID34919966
PMCPMC8891010
OpenAlexW4200358625

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.